PURPOSE: Phosphatidylinositol 3-kinase (PI3K) signaling is highly active in glioblastomas. We assessed pharmacokinetics, pharmacodynamics, and efficacy of the pan-PI3K inhibitor buparlisib in patients with recurrent glioblastoma with PI3K pathway activation. METHODS: This study was a multicenter, open-label, multi-arm, phase II trial in patients with PI3K pathway-activated glioblastoma at first or second recurrence. In cohort 1, patients scheduled for re-operation after progression received buparlisib for 7 to 13 days before surgery to evaluate brain penetration and modulation of the PI3K pathway in resected tumor tissue. In cohort 2, patients not eligible for re-operation received buparlisib until progression or unacceptable toxicity. Once daily oral buparlisib 100 mg was administered on a continuous 28-day schedule. Primary end points were PI3K pathway inhibition in tumor tissue and buparlisib pharmacokinetics in cohort 1 and 6-month progression-free survival (PFS6) in cohort 2. RESULTS: Sixty-five patients were treated (cohort 1, n = 15; cohort 2, n = 50). In cohort 1, reduction of phosphorylated AKTS473 immunohistochemistry score was achieved in six (42.8%) of 14 patients, but effects on phosphoribosomal protein S6S235/236 and proliferation were not significant. Tumor-to-plasma drug level was 1.0. In cohort 2, four (8%) of 50 patients reached 6-month PFS6, and the median PFS was 1.7 months (95% CI, 1.4 to 1.8 months). The most common grade 3 or greater adverse events related to treatment were lipase elevation (n = 7 [10.8%]), fatigue (n = 4 [6.2%]), hyperglycemia (n = 3 [4.6%]), and elevated ALT (n = 3 [4.6%]). CONCLUSION: Buparlisib had minimal single-agent efficacy in patients with PI3K-activated recurrent glioblastoma. Although buparlisib achieved significant brain penetration, the lack of clinical efficacy was explained by incomplete blockade of the PI3K pathway in tumor tissue. Integrative results suggest that additional study of PI3K inhibitors that achieve more-complete pathway inhibition may still be warranted.
PURPOSE:Phosphatidylinositol 3-kinase (PI3K) signaling is highly active in glioblastomas. We assessed pharmacokinetics, pharmacodynamics, and efficacy of the pan-PI3K inhibitor buparlisib in patients with recurrent glioblastoma with PI3K pathway activation. METHODS: This study was a multicenter, open-label, multi-arm, phase II trial in patients with PI3K pathway-activated glioblastoma at first or second recurrence. In cohort 1, patients scheduled for re-operation after progression received buparlisib for 7 to 13 days before surgery to evaluate brain penetration and modulation of the PI3K pathway in resected tumor tissue. In cohort 2, patients not eligible for re-operation received buparlisib until progression or unacceptable toxicity. Once daily oral buparlisib 100 mg was administered on a continuous 28-day schedule. Primary end points were PI3K pathway inhibition in tumor tissue and buparlisib pharmacokinetics in cohort 1 and 6-month progression-free survival (PFS6) in cohort 2. RESULTS: Sixty-five patients were treated (cohort 1, n = 15; cohort 2, n = 50). In cohort 1, reduction of phosphorylated AKTS473 immunohistochemistry score was achieved in six (42.8%) of 14 patients, but effects on phosphoribosomal protein S6S235/236 and proliferation were not significant. Tumor-to-plasma drug level was 1.0. In cohort 2, four (8%) of 50 patients reached 6-month PFS6, and the median PFS was 1.7 months (95% CI, 1.4 to 1.8 months). The most common grade 3 or greater adverse events related to treatment were lipase elevation (n = 7 [10.8%]), fatigue (n = 4 [6.2%]), hyperglycemia (n = 3 [4.6%]), and elevated ALT (n = 3 [4.6%]). CONCLUSION:Buparlisib had minimal single-agent efficacy in patients with PI3K-activated recurrent glioblastoma. Although buparlisib achieved significant brain penetration, the lack of clinical efficacy was explained by incomplete blockade of the PI3K pathway in tumor tissue. Integrative results suggest that additional study of PI3K inhibitors that achieve more-complete pathway inhibition may still be warranted.
Authors: Quinn T Ostrom; Haley Gittleman; Peter Liao; Toni Vecchione-Koval; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2017-11-06 Impact factor: 12.300
Authors: Cécile L Maire; Shakti Ramkissoon; Marika Hayashi; Sam Haidar; Lori Ramkissoon; Emmanuelle DiTomaso; Keith L Ligon Journal: Stem Cells Date: 2014-01 Impact factor: 6.277
Authors: Saskia M Brachmann; Julia Kleylein-Sohn; Swann Gaulis; Audrey Kauffmann; Marcel J J Blommers; Malika Kazic-Legueux; Laurent Laborde; Marc Hattenberger; Fabian Stauffer; Juliane Vaxelaire; Vincent Romanet; Chrystèle Henry; Masato Murakami; Daniel Alexander Guthy; Dario Sterker; Sebastian Bergling; Christopher Wilson; Thomas Brümmendorf; Christine Fritsch; Carlos Garcia-Echeverria; William R Sellers; Francesco Hofmann; Sauveur-Michel Maira Journal: Mol Cancer Ther Date: 2012-05-31 Impact factor: 6.261
Authors: Marshall W Pitz; Elizabeth A Eisenhauer; Mary V MacNeil; Brian Thiessen; Jacob C Easaw; David R Macdonald; David D Eisenstat; Ankineedu S Kakumanu; Muhammad Salim; Haji Chalchal; Jeremy Squire; Ming Sound Tsao; Suzanne Kamel-Reid; Shantanu Banerji; Dongsheng Tu; Jean Powers; Diana F Hausman; Warren P Mason Journal: Neuro Oncol Date: 2015-01-20 Impact factor: 12.300
Authors: Ingrid A Mayer; Vandana G Abramson; Luigi Formisano; Justin M Balko; Mónica V Estrada; Melinda E Sanders; Dejan Juric; David Solit; Michael F Berger; Helen H Won; Yisheng Li; Lewis C Cantley; Eric Winer; Carlos L Arteaga Journal: Clin Cancer Res Date: 2016-04-28 Impact factor: 12.531
Authors: Hoon Kim; Siyuan Zheng; Seyed S Amini; Selene M Virk; Tom Mikkelsen; Daniel J Brat; Jonna Grimsby; Carrie Sougnez; Florian Muller; Jian Hu; Andrew E Sloan; Mark L Cohen; Erwin G Van Meir; Lisa Scarpace; Peter W Laird; John N Weinstein; Eric S Lander; Stacey Gabriel; Gad Getz; Matthew Meyerson; Lynda Chin; Jill S Barnholtz-Sloan; Roel G W Verhaak Journal: Genome Res Date: 2015-02-03 Impact factor: 9.043
Authors: Tim F Cloughesy; Koji Yoshimoto; Phioanh Nghiemphu; Kevin Brown; Julie Dang; Shaojun Zhu; Teli Hsueh; Yinan Chen; Wei Wang; David Youngkin; Linda Liau; Neil Martin; Don Becker; Marvin Bergsneider; Albert Lai; Richard Green; Tom Oglesby; Michael Koleto; Jeff Trent; Steve Horvath; Paul S Mischel; Ingo K Mellinghoff; Charles L Sawyers Journal: PLoS Med Date: 2008-01-22 Impact factor: 11.069
Authors: Rehan Akbani; Patrick Kwok Shing Ng; Henrica M J Werner; Maria Shahmoradgoli; Fan Zhang; Zhenlin Ju; Wenbin Liu; Ji-Yeon Yang; Kosuke Yoshihara; Jun Li; Shiyun Ling; Elena G Seviour; Prahlad T Ram; John D Minna; Lixia Diao; Pan Tong; John V Heymach; Steven M Hill; Frank Dondelinger; Nicolas Städler; Lauren A Byers; Funda Meric-Bernstam; John N Weinstein; Bradley M Broom; Roeland G W Verhaak; Han Liang; Sach Mukherjee; Yiling Lu; Gordon B Mills Journal: Nat Commun Date: 2014-05-29 Impact factor: 14.919
Authors: Michael A Vogelbaum; Daria Krivosheya; Hamid Borghei-Razavi; Nader Sanai; Michael Weller; Wolfgang Wick; Riccardo Soffietti; David A Reardon; Manish K Aghi; Evanthia Galanis; Patrick Y Wen; Martin van den Bent; Susan Chang Journal: Neuro Oncol Date: 2020-11-26 Impact factor: 12.300
Authors: Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: Rachel A Freedman; Rebecca S Gelman; Nathalie Y R Agar; Sandro Santagata; Elizabeth C Randall; Begoña Gimenez-Cassina Lopez; Roisin M Connolly; Ian F Dunn; Catherine H Van Poznak; Carey K Anders; Michelle E Melisko; Kelly Silvestri; Christine M Cotter; Kathryn P Componeschi; Juan M Marte; Beverly Moy; Kimberly L Blackwell; Shannon L Puhalla; Nuhad Ibrahim; Timothy J Moynihan; Julie Nangia; Nadine Tung; Robyn Burns; Mothaffar F Rimawi; Ian E Krop; Antonio C Wolff; Eric P Winer; Nancy U Lin Journal: Clin Breast Cancer Date: 2019-08-22 Impact factor: 3.225
Authors: John D Hainsworth; Kevin P Becker; Tarek Mekhail; Sajeel A Chowdhary; Janice Faulkner Eakle; David Wright; Robert M Langdon; Kathleen J Yost; Gilbert Darin Anthony Padula; Kimberly West-Osterfield; Meredith Scarberry; Candice A Shaifer; Mythili Shastry; Howard A Burris; Kent Shih Journal: J Neurooncol Date: 2019-08-07 Impact factor: 4.130